Eisai publish series of BK Channel-Opening Agents

Eisai have published a series of Oxime and Oxime Ether 12,14-Dichlorodehydroabietic Acid derivative BK Channel-Opening Agents

Sucampos Lubiprostone safe and effective in Chronic Idiopathic Constipation

Sucampo have announced results from 3 open-labeled, long-term clinical trials of lubiprostone (AMITIZA) in patients with Chronic Idiopathic Constipation (CIC).

Glenmark/Lilly suspend trials with TRPV1 antagonist GRC 6211 in OA

Glenmark and Lilly have announced they have suspended further clinical development for TRPV1 antagonist GRC 6211 in Osteoarthritis pain.

NeurogesX Submit NDA for NGX-4010 for Treatment of Postherpetic Neuralgia (PHN)

NeurogesX have submitted a new drug application (NDA) with the U.S. FDAS for NGX-4010 Dermal Capsaicin Patch for the management of pain due to postherpetic neuralgia (PHN).

Valeant and GSK complete wordlwide collaboration for retigabine

Valeant has closed on its exclusive worldwide collaboration agreement with GlaxoSmithKline (GSK) for neuronal potassium channel opener retigabine, for the treatment of adult epilepsy patients with refractory partial onset seizures.  Valeant received an upfront payment of $125 million from GSK.

Icagen being Phase II trial of Senicapoc in Allergic Asthma

Icagen have initiated a Phase II clinical trial of KCa3.1 potassium ion channel blocker senicapoc in patients with allergic asthma.

Sciele/Plethora initiate Phase III trials of PSD502 for Premature Ejaculation

Sciele Pharma and Plethora Solutions have initiated a Phase III Trials for PSD502 for Premature Ejaculation. PSD502 is a proprietary formulation of two marketed drugs – lidocaine and prilocaine – dispensed by a metered dose aerosol.

Columbia Laboratories report Phase II results of lidocaine in vaginal dryness

Columbia Laboratories’ vaginally-administered lidocaine has demonstrated efficacy in the treatment of vaginal dryness through dysmenorrhea. although did not meet primary endpoint

Merck publish series of T-Type Calcium Channel blockers

Merck have published a series of  T-Type Calcium Channel blockers

Senicapoc blocks KCa3.1 currents in mast cells

Data presented at the 15th International Inflammation Research Association Conference show Icagen’s KCa3.1 potassium ion channel inhibitor senicapoc to potently block KCa3.1 potassium currents in isolated human lung mast cells and reduce the migration of these cells when exposed to an inflammatory stimulus.